Changes in prior authorization are now coming to the U.S. at the federal level. What does this mean for Canada?
As a former Oncology Drug Access Navigator (DAN), I understood that my patients needed treatment urgently for their cancer, and they didn’t have time to wait for it […]
In the fourth of our six-part series on comparing the PA process in Canada vs. the U.S. we address the importance of regular prior authorization program review.
In this third in our six-part series on prior authorization (PA) in Canada vs the U.S. we address the selective application of PA.
In our last blog we summarized the prior authorization (PA) reform experience in the United States […]
Since 2020, the conversation around improving the prior authorization process and experience has been gaining traction in Canada. Learn what Canadian stakeholders can take away from American developments.